Metformin Hydrochloride Teva

Metformin, the active ingredient in Metformin Hydrochloride Teva, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus by improving blood‑glucose control in adult patients. GNH USA supplies Metformin Hydrochloride Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is an oral antidiabetic that lowers elevated blood glucose levels in several related conditions.

Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c. Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes. Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea - Diarrhoea - Abdominal discomfort - Metallic taste - Loss of appetite - Flatulence

Serious or Rare Side Effects: - Lactic acidosis (potentially fatal) - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction - Vitamin B12 deficiency with long‑term use - Hypoglycaemia when combined with other glucose‑lowering agents

Metformin requires careful monitoring and patient education before and during therapy. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: evaluate liver enzymes as impaired function increases lactic acidosis risk. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Concomitant medications: review drugs that may affect renal clearance or increase acidosis risk. - Elderly patients: consider dose reduction and close monitoring. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): raise risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas: increase risk of hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - NSAIDs: may impair renal clearance of metformin.